BR0207102A - Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença - Google Patents

Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença

Info

Publication number
BR0207102A
BR0207102A BR0207102-9A BR0207102A BR0207102A BR 0207102 A BR0207102 A BR 0207102A BR 0207102 A BR0207102 A BR 0207102A BR 0207102 A BR0207102 A BR 0207102A
Authority
BR
Brazil
Prior art keywords
crystalline form
treatment
pharmaceutical composition
disease
prevention
Prior art date
Application number
BR0207102-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Takashi Takita
Keiichi Ohtsuka
Eiji Numagami
Susumu Harashima
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BR0207102A publication Critical patent/BR0207102A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR0207102-9A 2001-02-09 2002-02-06 Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença BR0207102A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001033128 2001-02-09
PCT/JP2002/000986 WO2002064609A1 (en) 2001-02-09 2002-02-06 Crystal of pyrimidine nucleoside derivative

Publications (1)

Publication Number Publication Date
BR0207102A true BR0207102A (pt) 2004-01-27

Family

ID=18896929

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0207102-9A BR0207102A (pt) 2001-02-09 2002-02-06 Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença
BRPI0207102A BRPI0207102A8 (pt) 2001-02-09 2002-02-06 forma cristalina, composição farmacêutica, e, uso de uma forma cristalina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0207102A BRPI0207102A8 (pt) 2001-02-09 2002-02-06 forma cristalina, composição farmacêutica, e, uso de uma forma cristalina.

Country Status (21)

Country Link
EP (1) EP1364959B1 (https=)
JP (2) JP3748536B2 (https=)
KR (1) KR100679904B1 (https=)
CN (1) CN100408591C (https=)
AT (1) ATE361929T1 (https=)
AU (1) AU2002230164B2 (https=)
BR (2) BR0207102A (https=)
CA (1) CA2437994C (https=)
CY (1) CY1106685T1 (https=)
CZ (1) CZ303241B6 (https=)
DE (1) DE60220024T2 (https=)
DK (1) DK1364959T3 (https=)
ES (1) ES2286237T3 (https=)
HU (1) HU229294B1 (https=)
IL (2) IL157216A0 (https=)
MX (1) MXPA03007123A (https=)
NZ (1) NZ527393A (https=)
PT (1) PT1364959E (https=)
RU (1) RU2256666C2 (https=)
WO (1) WO2002064609A1 (https=)
ZA (1) ZA200306121B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2265101B1 (en) 1999-09-02 2012-08-29 Ibiden Co., Ltd. Printed circuit board and method of manufacturing printed circuit board
US6876554B1 (en) 1999-09-02 2005-04-05 Ibiden Co., Ltd. Printing wiring board and method of producing the same and capacitor to be contained in printed wiring board
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP5066737B2 (ja) * 2007-04-06 2012-11-07 大鵬薬品工業株式会社 シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) * 2008-05-08 2008-06-18 Cyclacel Ltd Process
NZ589719A (en) 2008-06-09 2012-08-31 Cyclacel Ltd Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
HUE046177T2 (hu) 2011-04-14 2020-02-28 Cyclacel Ltd Szapacitabin és decitabin kombinációjának adagolási rendje akut mieloid leukémia kezelésére
KR102081042B1 (ko) * 2012-03-15 2020-02-26 셀젠 카르 엘엘씨 상피 성장 인자 수용체 키나제 억제제의 고체 형태
EP3268379B1 (en) 2015-03-09 2023-11-01 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside
CN112020363A (zh) 2017-12-22 2020-12-01 益力舒健康公司 烟酰胺核苷氯化物的结晶形式

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
RU2085557C1 (ru) * 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения

Also Published As

Publication number Publication date
HUP0303159A2 (hu) 2003-12-29
ES2286237T3 (es) 2007-12-01
CA2437994C (en) 2011-05-17
EP1364959A4 (en) 2004-03-24
MXPA03007123A (es) 2003-11-18
JP4356998B2 (ja) 2009-11-04
CZ20032111A3 (cs) 2003-12-17
IL157216A (en) 2008-03-20
DK1364959T3 (da) 2007-06-04
CN1501939A (zh) 2004-06-02
HU229294B1 (en) 2013-10-28
EP1364959B1 (en) 2007-05-09
JP3748536B2 (ja) 2006-02-22
CY1106685T1 (el) 2012-05-23
PT1364959E (pt) 2007-07-23
JP2006008699A (ja) 2006-01-12
DE60220024T2 (de) 2007-11-22
CA2437994A1 (en) 2002-08-22
HUP0303159A3 (en) 2007-06-28
NZ527393A (en) 2004-07-30
RU2003124648A (ru) 2005-02-27
KR20030081424A (ko) 2003-10-17
WO2002064609A1 (en) 2002-08-22
AU2002230164B2 (en) 2005-04-07
KR100679904B1 (ko) 2007-02-07
DE60220024D1 (en) 2007-06-21
CZ303241B6 (cs) 2012-06-13
JP2002308895A (ja) 2002-10-23
ZA200306121B (en) 2005-01-26
BRPI0207102A8 (pt) 2018-02-27
CN100408591C (zh) 2008-08-06
ATE361929T1 (de) 2007-06-15
EP1364959A1 (en) 2003-11-26
RU2256666C2 (ru) 2005-07-20
IL157216A0 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
NO20035524D0 (no) 4'-substituerte nukleosider
BR0109703A (pt) Derivados de piperazina
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DK1706403T3 (da) Imidazo[4,5-c]pyridinforbindelser og fremgangsmåder til antiviral behandling
GB0206860D0 (en) Compounds
MXPA04012965A (es) Inhibidores virales.
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
NO20040881L (no) Orale antidiabetes midler.
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
BR0207102A (pt) Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença
BR0113590A (pt) 7-oxo-piridopirimidinas
ATE238981T1 (de) Antitumorwirkstoffe
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
MXPA04006041A (es) Antivirales de piridoquinoxalina.
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
MXPA04004621A (es) Nucleotidos, preparaciones de los mismos y su utilizacion como inhibidores de polimerasas virales de arn.
NO20044548L (no) Fremgangsmate for fremstilling av 6-alkaliden-penemderivater
WO2003051838A3 (en) Protein kinase inhibitors
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
WO2004056832A3 (en) Epothilone derivatives
WO2004044174A3 (en) Topoisomerase-targeting agents

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL